OBJECTIVE:Methotrexate (MTX) taken as monotherapy is recommended as the initial disease-modifying antirheumatic drug for rheumatoid arthritis (RA). The purpose of this study was to examine outcomes of a blinded trial of initial MTX monotherapy with the option to step-up to combination therapy as compared to immediate combination therapy in patients with early, poor-prognosis RA. METHODS: In the Treatment of Early Rheumatoid Arthritis (TEAR) trial, 755 participants with early, poor-prognosis RA were randomized to receive MTX monotherapy or combination therapy (MTX plus etanercept or MTX plus sulfasalazine plus hydroxychloroquine). Participants randomized to receive MTX monotherapy stepped-up to combination therapy at 24 weeks if the Disease Activity Score in 28 joints using the erythrocyte sedimentation rate (DAS28-ESR) was ≥3.2. RESULTS: Attrition at 24 weeks was similar in the MTX monotherapy and combination groups. Of the 370 evaluable participants in the initialMTX group, 28% achieved low levels of disease activity and did not step-up to combination therapy (MTX monotherapy group). The mean ± SD DAS28-ESR in participants continuing to take MTX monotherapy at week 102 was 2.7 ± 1.2, which is similar to that in participants who were randomized to immediate combination therapy (2.9 ± 1.2). Participants who received MTX monotherapy had less radiographic progression at week 102 as compared to those who received immediate combination therapy (mean ± SD change in modified Sharp score 0.2 ± 1.1 versus 1.1 ± 6.4). Participants assigned to initial MTX who required step-up to combination therapy at 24 weeks (72%) demonstrated similar DAS28-ESR values (3.5 ± 1.3 versus 3.2 ± 1.3 at week 48) and radiographic progression (change in modified Sharp score 1.2 ± 4.1 versus 1.1 ± 6.4 at week 102) as those assigned to immediate combination therapy. The results for either of the immediate combination approaches, whether triple therapy or MTX plus etanercept, were similar. CONCLUSION: These results in patients with early, poor prognosis RA validate the strategy of starting with MTX monotherapy. This study is the first to demonstrate in a blinded trial that initial MTX monotherapy with the option to step-up to combination therapy results in similar outcomes to immediate combination therapy. Approximately 30% of patients will not need combination therapy, and the 70% who will need it are clinically and radiographically indistinguishable from those who were randomized to receive immediate combination therapy.
RCT Entities:
OBJECTIVE:Methotrexate (MTX) taken as monotherapy is recommended as the initial disease-modifying antirheumatic drug for rheumatoid arthritis (RA). The purpose of this study was to examine outcomes of a blinded trial of initial MTX monotherapy with the option to step-up to combination therapy as compared to immediate combination therapy in patients with early, poor-prognosis RA. METHODS: In the Treatment of Early Rheumatoid Arthritis (TEAR) trial, 755 participants with early, poor-prognosis RA were randomized to receive MTX monotherapy or combination therapy (MTX plus etanercept or MTX plus sulfasalazine plus hydroxychloroquine). Participants randomized to receive MTX monotherapy stepped-up to combination therapy at 24 weeks if the Disease Activity Score in 28 joints using the erythrocyte sedimentation rate (DAS28-ESR) was ≥3.2. RESULTS: Attrition at 24 weeks was similar in the MTX monotherapy and combination groups. Of the 370 evaluable participants in the initial MTX group, 28% achieved low levels of disease activity and did not step-up to combination therapy (MTX monotherapy group). The mean ± SD DAS28-ESR in participants continuing to take MTX monotherapy at week 102 was 2.7 ± 1.2, which is similar to that in participants who were randomized to immediate combination therapy (2.9 ± 1.2). Participants who received MTX monotherapy had less radiographic progression at week 102 as compared to those who received immediate combination therapy (mean ± SD change in modified Sharp score 0.2 ± 1.1 versus 1.1 ± 6.4). Participants assigned to initial MTX who required step-up to combination therapy at 24 weeks (72%) demonstrated similar DAS28-ESR values (3.5 ± 1.3 versus 3.2 ± 1.3 at week 48) and radiographic progression (change in modified Sharp score 1.2 ± 4.1 versus 1.1 ± 6.4 at week 102) as those assigned to immediate combination therapy. The results for either of the immediate combination approaches, whether triple therapy or MTX plus etanercept, were similar. CONCLUSION: These results in patients with early, poor prognosis RA validate the strategy of starting with MTX monotherapy. This study is the first to demonstrate in a blinded trial that initial MTX monotherapy with the option to step-up to combination therapy results in similar outcomes to immediate combination therapy. Approximately 30% of patients will not need combination therapy, and the 70% who will need it are clinically and radiographically indistinguishable from those who were randomized to receive immediate combination therapy.
Authors: T Möttönen; P Hannonen; M Leirisalo-Repo; M Nissilä; H Kautiainen; M Korpela; L Laasonen; H Julkunen; R Luukkainen; K Vuori; L Paimela; H Blåfield; M Hakala; K Ilva; U Yli-Kerttula; K Puolakka; P Järvinen; M Hakola; H Piirainen; J Ahonen; I Pälvimäki; S Forsberg; K Koota; C Friman Journal: Lancet Date: 1999-05-08 Impact factor: 79.321
Authors: Paul Emery; Roy Fleischmann; Anna Filipowicz-Sosnowska; Joy Schechtman; Leszek Szczepanski; Arthur Kavanaugh; Artur J Racewicz; Ronald F van Vollenhoven; Nicole F Li; Sunil Agarwal; Eva W Hessey; Timothy M Shaw Journal: Arthritis Rheum Date: 2006-05
Authors: Yvonne P M Goekoop-Ruiterman; Jeska K de Vries-Bouwstra; Cornelia F Allaart; Derkjen van Zeben; Pit J S M Kerstens; J Mieke W Hazes; Aelko H Zwinderman; André J Peeters; Johanna M de Jonge-Bok; Constant Mallée; Wim M de Beus; Peter B J de Sonnaville; Jacques A P M Ewals; Ferdinand C Breedveld; Ben A C Dijkmans Journal: Ann Intern Med Date: 2007-03-20 Impact factor: 25.391
Authors: D van der Heijde; L Klareskog; M Boers; R Landewé; C Codreanu; H D Bolosiu; R Pedersen; S Fatenejad Journal: Ann Rheum Dis Date: 2005-04-28 Impact factor: 19.103
Authors: Ferdinand C Breedveld; Michael H Weisman; Arthur F Kavanaugh; Stanley B Cohen; Karel Pavelka; Ronald van Vollenhoven; John Sharp; John L Perez; George T Spencer-Green Journal: Arthritis Rheum Date: 2006-01
Authors: James R O'Dell; Jennifer R Elliott; Jack A Mallek; Ted R Mikuls; Cynthia A Weaver; Scott Glickstein; Kent M Blakely; Raymond Hausch; Rob D Leff Journal: Arthritis Rheum Date: 2006-02
Authors: Mark C Genovese; James D McKay; Evgeny L Nasonov; Eduardo F Mysler; Nilzio A da Silva; Emma Alecock; Thasia Woodworth; Juan J Gomez-Reino Journal: Arthritis Rheum Date: 2008-10
Authors: Paul Emery; Ferdinand C Breedveld; Stephen Hall; Patrick Durez; David J Chang; Deborah Robertson; Amitabh Singh; Ronald D Pedersen; Andrew S Koenig; Bruce Freundlich Journal: Lancet Date: 2008-07-16 Impact factor: 79.321
Authors: D van der Heijde; L Klareskog; R Landewé; G A W Bruyn; A Cantagrel; P Durez; G Herrero-Beaumont; Y Molad; C Codreanu; G Valentini; R Zahora; R Pedersen; D MacPeek; J Wajdula; S Fatenejad Journal: Arthritis Rheum Date: 2007-12
Authors: D Aletaha; R Landewe; T Karonitsch; J Bathon; M Boers; C Bombardier; S Bombardieri; H Choi; B Combe; M Dougados; P Emery; J Gomez-Reino; E Keystone; G Koch; T K Kvien; E Martin-Mola; M Matucci-Cerinic; K Michaud; J O'Dell; H Paulus; T Pincus; P Richards; L Simon; J Siegel; J S Smolen; T Sokka; V Strand; P Tugwell; D van der Heijde; P van Riel; S Vlad; R van Vollenhoven; M Ward; M Weinblatt; G Wells; B White; F Wolfe; B Zhang; A Zink; D Felson Journal: Arthritis Rheum Date: 2008-10-15
Authors: Veena K Ranganath; Kambiz Motamedi; Espen A Haavardsholm; Paul Maranian; David Elashoff; Fiona McQueen; Erin L Duffy; Joan M Bathon; Jeffrey R Curtis; Weiling Chen; Larry Moreland; James Louie; Sogol Amjadi; James O'Dell; Stacey S Cofield; E William St Clair; S Louis Bridges; Harold E Paulus Journal: Arthritis Care Res (Hoboken) Date: 2015-07 Impact factor: 4.794
Authors: Jie Zhang; Fenglong Xie; Elizabeth Delzell; Huifeng Yun; James D Lewis; Kevin Haynes; Lang Chen; Timothy Beukelman; Kenneth G Saag; Jeffrey R Curtis Journal: Arthritis Care Res (Hoboken) Date: 2015-05 Impact factor: 4.794
Authors: Arthur M Mandelin; Philip J Homan; Alexander M Shaffer; Carla M Cuda; Salina T Dominguez; Emily Bacalao; Mary Carns; Monique Hinchcliff; Jungwha Lee; Kathleen Aren; Anjali Thakrar; Anna B Montgomery; S Louis Bridges; Joan M Bathon; John P Atkinson; David A Fox; Eric L Matteson; Christopher D Buckley; Costantino Pitzalis; Deborah Parks; Laura B Hughes; Laura Geraldino-Pardilla; Robert Ike; Kristine Phillips; Kerry Wright; Andrew Filer; Stephen Kelly; Eric M Ruderman; Vince Morgan; Hiam Abdala-Valencia; Alexander V Misharin; G Scott Budinger; Elizabeth T Bartom; Richard M Pope; Harris Perlman; Deborah R Winter Journal: Arthritis Rheumatol Date: 2018-05-03 Impact factor: 10.995
Authors: Brent A Luedders; Tate M Johnson; Harlan Sayles; Geoffrey M Thiele; Ted R Mikuls; James R O'Dell; Bryant R England Journal: Semin Arthritis Rheum Date: 2020-06-17 Impact factor: 5.532